QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AVIR

QT53Atea Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.36
+0.03+0.69%
OverviewShort InterestFilings
AVIRQT53Atea Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
4.36+0.69%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
1.36
Insider Own-
Shs Outstand80.03M
Perf Week0.00%
Market Cap346.52MForward P/E-EPS next Y-1.38Insider Trans1.74%Shs Float-Perf Month5.06%
Enterprise Value267.83MPEG0.08EPS next Q-0.56Inst Own-Short Float-Perf Quarter-27.33%
Income-171283521.00P/S0.00EPS this Y-241.54%Inst Trans-Short Ratio-Perf Half Y35.40%
Sales-P/B1.47EPS next Y28.05%ROA-63.47%Short Interest-Perf YTD22.13%
Book/sh5.14P/C-EPS next 5Y-ROE-57.01%52W High6.45 -32.40%Perf Year35.83%
Cash/sh5.31P/FCF-EPS past 3/5Y-ROIC-78.11%52W Low2.78 56.83%Perf 3Y-
Dividend Est.-EV/EBITDA-1.49Sales past 3/5Y-Gross Margin0.00%Volatility3.37% 3.22%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-5.50%Oper. Margin0.00%ATR (14)0.22Perf 10Y-
Dividend Ex-Date-Quick Ratio7.89Sales Y/Y TTM-Profit Margin0.00%RSI (14)43.69Recom3.00
Dividend Gr. 3/5Y-Current Ratio7.89EPS Q/Q-42.50%SMA20-0.79%Beta0.78Target Price10.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-12.02%Rel Volume2.01Prev Close4.33
Employees56LT Debt/Eq0.00EarningsAug 06SMA2006.11%Avg Volume302.71KPrice4.36
IPO DateOct 30, 2020Option/ShortYes / YesEPS/Sales Surpr.5.00% -Net Debt/EBITDA0.44Volume607,583Change0.69%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-09-26ReiteratedEvercore ISI$6.00 → $10
Aug-13-24UpgradeMorgan StanleyUnderweight → Equal Weight$6.88
Aug-10-23DowngradeJP MorganNeutral → Underweight
Jan-06-22DowngradeMorgan StanleyEqual Weight → Underweight
Nov-18-21DowngradeSVB LeerinkOutperform → Market Perform
Oct-20-21DowngradeJP MorganOverweight → Neutral
Oct-05-21DowngradeMorgan StanleyOverweight → Equal Weight
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue35100
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A168083
Gross Profit1840-83
Selling, General and Administrative Excl. Other463349
Research and Development168148145
Other Operating Expense-1680-84
Operating Income139-181-193
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)0-16-61
Net Income Before Taxes139-165-167
Income Taxes17-61
Consolidated Net Income122-158-168
Net Income From Continuing Operations122-158-168
Net Income122-158-168
EPS (Recurring)1.46-1.94-2.00
EPS (Basic, Before Extraordinaries)1.46-1.94-2.00
EPS (Diluted)1.36-1.94-2.00
EBITDA139-164-132
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
3.21——
Price To Sales Ratio
1.03——
Gross Margin52.42——
Operating Margin39.60——
Net Margin34.76——
Shares Outstanding838184
Market Capitalization362289—
Operating Lease Expense
———
Insider Trading Volume
$4.65$4.30$3.95$3.60$3.25● Close Price0.00K6.36K12.72K19.08K25.45KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Murphy Polly A.DirectorMay 18 '26Buy4.176,10025,44692,145May 21 12:00 AM
Murphy Polly A.DirectorMay 18 '25Buy4.176,10025,44692,145May 20 12:00 AM
Corcoran AndreaSee RemarksMar 11 '26Option Exercise1.24120,000148,800823,576Mar 13 12:00 AM
Sommadossi Jean-PierrePresident, CEO, and ChairmanFeb 03 '26Option Exercise1.24600,000744,000767,830Feb 03 12:00 AM
Vavricka JohnChief Commercial OfficerJan 31 '26Option Exercise0.0050,833094,164Feb 03 12:00 AM
Hammond Janet MJChief Development OfficerJan 31 '26Option Exercise0.0069,3000141,801Feb 03 12:00 AM
Corcoran AndreaSee RemarksJan 31 '26Option Exercise0.0065,3660779,680Feb 03 12:00 AM
Sommadossi Jean-PierrePresident, CEO, and ChairmanJan 31 '26Option Exercise0.00372,5000573,923Feb 03 12:00 AM
Foster WayneEVP, Chief Accounting OfficerJan 31 '26Option Exercise0.0049,333091,461Feb 03 12:00 AM
Horga Maria ArantxaChief Medical OfficerJan 31 '26Option Exercise0.0061,0330112,159Feb 03 12:00 AM
Murphy Polly A.DirectorJun 20 '25Option Exercise0.0059,200086,045Jun 24 12:00 AM
BERGER FRANKLIN MDirectorJun 20 '25Option Exercise0.0059,2000506,497Jun 24 12:00 AM
Duncan Barbara GayleDirectorJun 20 '25Option Exercise0.0059,200062,750Jun 24 12:00 AM
Polsky BruceDirectorJun 20 '25Option Exercise0.0059,200095,206Jun 24 12:00 AM
Adams Jerome M.DirectorJun 20 '25Option Exercise0.0059,200062,750Jun 24 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR